ITCH and breast carcinoma: Label free proteomic results showed an increase in the level of ITCH, an E3-ligase, co-immunoprecipitated in OMSi treatment (Figure 5C, Supplementary Table S3) when compared to DMSO or TMG treatment (Supplementary Figure S4C), suggesting that ITCH may ubiquitinate GATAD2B in breast cancer cells.